CriticalDirect oral anticoagulants (factor Xa inhibitors)×Antiepileptics. Fatty acid derivatives
Updated · Methodology
Mechanism
The antiepileptic drug table of the European Heart Rhythm Association (EHRA) practical guide gives induction or inhibition of the CYP3A4 enzyme and the efflux transporter P-glycoprotein (P-gp) as the interaction route for valproic acid. The same table lists apixaban as a substrate of P-gp and of CYP3A4 (≈25%) (EHRA 2021). The guide's text says that valproate may have unpredictable effects on CYP3A4 and that, in animal and/or human studies, valproic acid may decrease the effect of direct oral anticoagulants by inducing P-gp activity (EHRA 2021). The valproate labels put it differently: the Spanish SmPC says valproate has no enzyme-inducing effect (valproate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the US label calls it a weak inhibitor of some cytochrome P450 isozymes (valproate label, US Food and Drug Administration, FDA). A second mechanism does not depend on apixaban levels: valproate causes dose-related thrombocytopenia, inhibits the secondary phase of platelet aggregation and may cause abnormal coagulation parameters (valproate label, FDA), and the Spanish SmPC says that use with anticoagulants may increase the bleeding tendency (valproate SmPC, AEMPS).
Symptoms
According to the EHRA table legend, valproic acid lowers apixaban levels, which carries a risk of thrombosis: stroke or systemic embolism in atrial fibrillation, and recurrent deep vein thrombosis or pulmonary embolism in venous thromboembolism (EHRA 2021). Valproate itself commonly causes thrombocytopenia and bleeding (valproate SmPC, AEMPS). Signs include bruising, red or purple spots on the skin, bleeding from the nose or mouth, vomiting blood or material that looks like coffee grounds, and blood in the stools or black stools (valproate label, FDA). A retrospective cohort from Taiwan found bleeding more often when direct oral anticoagulants and valproic acid were prescribed together, but the authors note that this result may not apply to other patient groups (EHRA 2021).
Management
The combination is contraindicated in the practical guide of the European Heart Rhythm Association (EHRA): its antiepileptic drug table marks the apixaban and valproic acid cell as contraindicated because of reduced anticoagulant levels (EHRA 2021). If antiepileptic treatment cannot be avoided in a person with atrial fibrillation who takes a direct oral anticoagulant, the guide calls for vigilance for drug interactions and regular joint review by the cardiologist, neurologist, primary care physician and clinical pharmacist (EHRA 2021). Anticoagulant plasma level measurements are often proposed in this setting, but there is no outcome trial evidence for dosing by measured levels, so the authors advise treating such patients at expert centres with experience in these measurements and their interpretation (EHRA 2021). Check a full blood count with platelets, bleeding time and coagulation tests before starting valproate, before surgery and in case of spontaneous bruising or bleeding (valproate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With anticoagulants, the same SmPC recommends regular monitoring of blood coagulation (valproate SmPC, AEMPS). The US label recommends blood counts and coagulation tests before starting valproate and at periodic intervals, and states that haemorrhage, bruising or a disorder of haemostasis is an indication to reduce the valproate dose or stop it (valproate label, US Food and Drug Administration, FDA). If valproate is started in a person who already takes an anticoagulant, monitor coagulation tests (valproate label, FDA). The protein-binding data in that section of the US label come from warfarin (valproate label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Depakote (divalproex sodium) delayed-release tablets prescribing information (2026)– FDA, DailyMed, Depakote, AbbVie Inc., setid 08a65cf4-7749-4ceb-6895-8f4805e2b01f, revisión 03/2026, sección 5.15
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Ácido valproico, Depakine Crono 500 mg (nº registro 60350) (2026)– AEMPS, CIMA, nº registro 60350 (Depakine Crono 500 mg comprimidos de liberación prolongada, Sanofi), revisión 09/2026, secciones 4.1, 4.2, 4.4, 4.5 y 4.6